Masimo Corp. Stock
€156.00
Your prediction
Masimo Corp. Stock
Pros and Cons of Masimo Corp. in the next few years
Pros
Cons
Performance of Masimo Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Masimo Corp. | - | 0.000% | 1.299% | 6.412% | 40.288% | 5.441% | -22.349% |
| Haemonetics Corp. | -2.360% | 5.426% | 17.241% | - | -0.730% | - | - |
| Bio-Rad Labs Inc. A | 1.300% | 5.897% | 2.662% | 25.816% | 1.667% | -21.450% | -50.991% |
| CONMED Corp. | 0.640% | 10.638% | 2.632% | -30.045% | -10.857% | -74.000% | -73.559% |
Comments
News
This $7 Million Masimo Exit Came Before a 34% Surge on $9.9 Billion Acquisition
On February 17, 2026, Bridger Management disclosed in a Securities and Exchange Commission (SEC) filing that it sold out its entire position in Masimo (NASDAQ:MASI).
According to a Securities and
This Fund Built a $26 Million Stake in a Medical Tech Stock That's Soaring After a $9.9 Billion Deal Announcement
On February 17, 2026, Parkman Healthcare Partners disclosed a new position in Masimo Corporation (NASDAQ:MASI), acquiring 200,000 shares in the fourth quarter worth an estimated $26.01 million at
Naya Capital Adds Masimo Shares
According to an SEC filing dated Feb. 18, Naya Capital Management UK Ltd disclosed a new position in Masimo (NASDAQ:MASI), acquiring nearly 1.6 million shares.
Masimo is a leading provider of


